BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Distler O, Assassi S, Cottin V, Cutolo M, Danoff SK, Denton CP, Distler JHW, Hoffmann-Vold AM, Johnson SR, Müller Ladner U, Smith V, Volkmann ER, Maher TM. Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J 2020;55:1902026. [PMID: 32079645 DOI: 10.1183/13993003.02026-2019] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 22.3] [Reference Citation Analysis]
Number Citing Articles
1 Volkmann ER, Andréasson K, Smith V. Systemic sclerosis. Lancet 2023;401:304-18. [PMID: 36442487 DOI: 10.1016/S0140-6736(22)01692-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Li H, Zhang X, Yu L, Shang J, Fan J, Feng X, Zhang R, Ren J, Guo Q, Duan X. Comparing clinical characteristics of systemic sclerosis with or without interstitial lung disease: A cross-sectional study from a single center of the Chinese Rheumatism Data Center. Front Med (Lausanne) 2022;9:1061738. [PMID: 36561716 DOI: 10.3389/fmed.2022.1061738] [Reference Citation Analysis]
3 Schmidkonz C, Kuwert T, Atzinger A, Cordes M, Schett G, Ramming A, Götz T. Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging. J Nucl Med 2022;63:1786-92. [PMID: 36109182 DOI: 10.2967/jnumed.122.264205] [Reference Citation Analysis]
4 Elhai M, Sritharan N, Boubaya M, Balbir-gurman A, Siegert E, Hachulla E, de Vries-bouwstra J, Riemekasten G, Distler JHW, Rosato E, Del Galdo F, Mendoza FA, Furst DE, de la Puente C, Hoffmann-vold A, Gabrielli A, Distler O, Bloch-queyrat C, Allanore Y, Matucci Cerinic M, Walker U, Iannone F, Jordan S, Becvar R, Kowal Bielecka O, Cutolo M, Cuomo G, Kedor C, Rednic S, Avouac J, Vlachoyiannopoulos P, Montecucco C, Stork J, Inanc M, Carreira PE, Novak S, Czirják L, Iudici M, Kucharz EJ, Zanatta E, Perdan-pirkmajer K, Coleiro B, Moroncini G, Farge Bancel D, Airò P, Hesselstrand R, Radic M, Braun-moscovici Y, Lo Monaco A, Hunzelmann N, Pellerito R, Giollo A, Morovic-vergles J, Denton C, Vonk M, Damjanov N, Henes J, Ortiz Santamaria V, Heitmann S, Krasowska D, Hasler P, Kohm M, Foeldvari I, Bajocchi G, Salvador MJ, Stamenkovic B, Selmi CF, Tikly M, Ananieva LP, Herrick A, Müller-ladner U, De Palma R, Engelhart M, Szücs G, Sobrino Grande C, Midtvedt Ø, Launay D, Riccieri V, Ionescu RM, Sha A, Gheorghiu AM, Sunderkötter C, Ingegnoli F, Mouthon L, Smith V, Cantatore FP, Ullman S, Alberto von Mühlen C, Pozzi MR, Eyerich K, Wiland P, Vanthuyne M, Alegre-sancho JJ, Herrmann K, De Langhe E, Anic B, Üprus M, Yavuz S, Granel B, de Souza Müller C, Busquets J, Agachi S, Stebbings S, Mathieu D, Sampaio-barros PD, Stamp L, Solanki K, Veale D, Loyo E, Li M, Abdel Atty Mohamed WA, Gigante A, Oksel F, Tanaseanu C, Foti R, Ancuta C, Maurer B, van Laar J, Kayser C, Fathi N, García de la Peña Lefebvre P, Sibilia J, Litinsky I, Abignano G, Seskute G, Saketkoo LA, Kerzberg E, Bianchi W, Castellví I, Limonta M, Rimar D, Couto M, Spertini F, Marcoccia A, Kahl S, Hsu IM, Martin T, Moiseev S, Chung LS, Schmeiser T, Majewski D, Zdrojewski Z, Martínez-barrio J, Bernardino V, Sommerlatte S, Levy Y, Rezus E, Nuri Pamuk O, Sarzi Puttini P, Poormoghim H, Kötter I, Cuomo G, Gaches F, Belloli L, Sfikakis P, Markus J, Feldman GR, Ramazan A, Scherer H, Truchetet M, Lescoat A, Dagna L, van Laar J, Rudnicka L, Oliveira S, Atzeni F, Kuwana M, Mekinian A, Martin M, Tanaka Y. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort. The Lancet Rheumatology 2022;4:e785-e794. [DOI: 10.1016/s2665-9913(22)00217-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Hoffmann-vold A, Brunborg C, Airò P, Ananyeva LP, Czirják L, Guiducci S, Hachulla E, Li M, Mihai C, Riemekasten G, Sfikakis P, Valentini G, Kowal-bielecka O, Allanore Y, Distler O. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research. Chest 2022. [DOI: 10.1016/j.chest.2022.09.044] [Reference Citation Analysis]
6 Hambly N, Farooqi MM, Dvorkin-Gheva A, Donohoe K, Garlick K, Scallan C, Chong SG, MacIsaac S, Assayag D, Johannson KA, Fell CD, Marcoux V, Manganas H, Morisset J, Comes A, Fisher JH, Shapera S, Gershon AS, To T, Wong AW, Sadatsafavi M, Wilcox PG, Halayko AJ, Khalil N, Cox G, Richeldi L, Ryerson CJ, Kolb M. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Respir J 2022;60:2102571. [PMID: 35273032 DOI: 10.1183/13993003.02571-2021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
7 Cottin V, Martinez FJ, Smith V, Walsh SL. Multidisciplinary teams in the clinical care of fibrotic interstitial lung disease: current perspectives. Eur Respir Rev 2022;31:220003. [DOI: 10.1183/16000617.0003-2022] [Reference Citation Analysis]
8 Cole A, Denton CP. Biomarkers in Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD). Curr Treat Options in Rheum. [DOI: 10.1007/s40674-022-00196-3] [Reference Citation Analysis]
9 Campochiaro C, Lazzaroni MG, Bruni C, Zanatta E, De Luca G, Matucci-Cerinic M. Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review. Ther Adv Musculoskelet Dis 2022;14:1759720X221116408. [PMID: 36051631 DOI: 10.1177/1759720X221116408] [Reference Citation Analysis]
10 Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. The Lancet 2022;400:769-86. [DOI: 10.1016/s0140-6736(22)01052-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Chikhoune L, Brousseau T, Morell-dubois S, Farhat MM, Maillard H, Ledoult E, Lambert M, Yelnik C, Sanges S, Sobanski V, Hachulla E, Launay D. Association between Routine Laboratory Parameters and the Severity and Progression of Systemic Sclerosis. JCM 2022;11:5087. [DOI: 10.3390/jcm11175087] [Reference Citation Analysis]
12 Jang HJ, Woo A, Kim SY, Yong SH, Park Y, Chung K, Lee SH, Leem AY, Lee SH, Kim EY, Jung JY, Kang YA, Kim YS, Park MS. Characteristics, mortality, and risk factors in patients with systemic sclerosis-associated interstitial lung disease.. [DOI: 10.21203/rs.3.rs-1923905/v1] [Reference Citation Analysis]
13 Molina-Molina M, Castellví I, Valenzuela C, Ramirez J, Rodríguez Portal JA, Franquet T, Narváez J. Management of progressive pulmonary fibrosis associated with connective tissue disease. Expert Rev Respir Med 2022. [PMID: 35912842 DOI: 10.1080/17476348.2022.2107508] [Reference Citation Analysis]
14 Gál P, Brábek J, Holub M, Jakubek M, Šedo A, Lacina L, Strnadová K, Dubový P, Hornychová H, Ryška A, Smetana K Jr. Autoimmunity, cancer and COVID-19 abnormally activate wound healing pathways: critical role of inflammation. Histochem Cell Biol 2022. [PMID: 35867145 DOI: 10.1007/s00418-022-02140-x] [Reference Citation Analysis]
15 Lafyatis R, Valenzi E. Assessment of disease outcome measures in systemic sclerosis. Nat Rev Rheumatol 2022. [PMID: 35859133 DOI: 10.1038/s41584-022-00803-6] [Reference Citation Analysis]
16 Assassi S, Distler O, Allanore Y, Ogura T, Varga J, Vettori S, Crestani B, Voss F, Alves M, Stowasser S, Maher TM; SENSCIS trial investigators. Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial. ACR Open Rheumatol 2022. [PMID: 35852465 DOI: 10.1002/acr2.11483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 RuizdelRio J, Muñoz P, Carreira P, Maestro D, Pablos JL, Palanca A, Merino J, Serrano-Mollar A, Merino R, Tamayo E, Lopez-Hoyos M, Diaz-Gonzalez F, Martinez-Taboada V, Villar AV. Profibrotic Role of Inducible Heat Shock Protein 90α Isoform in Systemic Sclerosis. J Immunol 2022;209:38-48. [PMID: 35715007 DOI: 10.4049/jimmunol.2100430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Liu GY, Budinger GRS, Dematte JE. Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. BMJ. [DOI: 10.1136/bmj-2021-066354] [Reference Citation Analysis]
19 Temiz Karadağ D, Çakir Ö, Tuncer Kuru F, Yazici A, Çefle A. Sistemik Sklerozis İlişkili İnterstisyel Akciğer Hastalığında Tedavi Yanıtını İzlemede Bilgisayarlı Tomografiye Dayalı Yeni Parametreler. Uludağ Üniversitesi Tıp Fakültesi Dergisi 2022. [DOI: 10.32708/uutfd.1081311] [Reference Citation Analysis]
20 Huang B, Li J, Zhao J. Screening and identification of potential biomarkers and therapeutic targets for systemic sclerosis-associated interstitial lung disease. Arch Rheumatol 2021;36:548-59. [PMID: 35382367 DOI: 10.46497/ArchRheumatol.2021.8625] [Reference Citation Analysis]
21 Case AH. Clinical Overview of Progressive Fibrotic Interstitial Lung Disease. Front Med (Lausanne) 2022;9:858339. [PMID: 35372405 DOI: 10.3389/fmed.2022.858339] [Reference Citation Analysis]
22 Manetti M, Rosa I, Fioretto BS, Matucci-Cerinic M, Romano E. Decreased Serum Levels of SIRT1 and SIRT3 Correlate with Severity of Skin and Lung Fibrosis and Peripheral Microvasculopathy in Systemic Sclerosis. J Clin Med 2022;11:1362. [PMID: 35268452 DOI: 10.3390/jcm11051362] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Lescoat A, Jouneau S, Uzunhan Y, Jégo P, Cottin V, Hachulla E. [Systemic sclerosis-related interstitial lung disease: Diagnostic and therapeutic strategy in the light of recent clinical trials]. Rev Med Interne 2022:S0248-8663(21)01144-9. [PMID: 35181160 DOI: 10.1016/j.revmed.2021.12.003] [Reference Citation Analysis]
24 Acosta Fernández O, Aburto Barrenetxea M, Llanos González AB, Rodríguez Nieto MJ, Molina Molina M, Valenzuela C. Manejo de las enfermedades pulmonares intersticiales difusas (EPID) asociadas a enfermedades autoinmunes, por el neumólogo en las diferentes unidades de EPID en España. Open Respiratory Archives 2022. [DOI: 10.1016/j.opresp.2022.100160] [Reference Citation Analysis]
25 Bayati P, Poormoghim H, Mojtabavi N. Aberrant expression of miR-138 as a novel diagnostic biomarker in systemic sclerosis. Biomark�Insights 2022;17:117727192211354. [DOI: 10.1177/11772719221135442] [Reference Citation Analysis]
26 Ruaro B, Baratella E, Confalonieri P, Confalonieri M, Vassallo FG, Wade B, Geri P, Pozzan R, Caforio G, Marrocchio C, Cova MA, Salton F. High-Resolution Computed Tomography and Lung Ultrasound in Patients with Systemic Sclerosis: Which One to Choose? Diagnostics (Basel) 2021;11:2293. [PMID: 34943531 DOI: 10.3390/diagnostics11122293] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
27 Watanabe S, Kase K, Saeki K, Ohkura N, Murata A, Waseda Y, Takato H, Ichikawa Y, Yasui M, Kasahara K. Kinetic changes in serum KL-6 levels predict disease progression in patients with systemic sclerosis-associated interstitial lung disease. Respir Med 2021;191:106689. [PMID: 34844174 DOI: 10.1016/j.rmed.2021.106689] [Reference Citation Analysis]
28 Bosello SL, Beretta L, Del Papa N, Harari S, Palmucci S, Pesci A, Rechichi G, Varone F, Sebastiani M. Interstitial Lung Disease Associated With Autoimmune Rheumatic Diseases: Checklists for Clinical Practice. Front Med (Lausanne) 2021;8:732761. [PMID: 34722574 DOI: 10.3389/fmed.2021.732761] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
29 Shirai Y, Fukue R, Kaneko Y, Kuwana M. Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease. Diagnostics (Basel) 2021;11:2007. [PMID: 34829353 DOI: 10.3390/diagnostics11112007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Ruaro B, Baratella E, Confalonieri P, Wade B, Marrocchio C, Geri P, Busca A, Pozzan R, Andrisano AG, Cova MA, Confalonieri M, Salton F. High-Resolution Computed Tomography: Lights and Shadows in Improving Care for SSc-ILD Patients. Diagnostics (Basel) 2021;11:1960. [PMID: 34829307 DOI: 10.3390/diagnostics11111960] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
31 Murdaca G, Caprioli S, Tonacci A, Billeci L, Greco M, Negrini S, Cittadini G, Zentilin P, Ventura Spagnolo E, Gangemi S. A Machine Learning Application to Predict Early Lung Involvement in Scleroderma: A Feasibility Evaluation. Diagnostics (Basel) 2021;11:1880. [PMID: 34679580 DOI: 10.3390/diagnostics11101880] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
32 Syed Gaggatur N, Sange AH, Srinivas N, Sarnaik MK, Modi S, Pisipati Y, Vaidya S, Sange I. Systemic Sclerosis: Highlighting Respiratory Complications and Significance of Early Screening. Cureus 2021;13:e17291. [PMID: 34552830 DOI: 10.7759/cureus.17291] [Reference Citation Analysis]
33 Buschulte K, Hoffmann-Vold AM, Dobrota RD, Höger P, Krause A, Kreuter M. [Treatment of lung fibrosis in systemic rheumatic diseases (new treatment)]. Z Rheumatol 2021;80:743-54. [PMID: 34505934 DOI: 10.1007/s00393-021-01067-3] [Reference Citation Analysis]
34 van Leeuwen NM, Maurits M, Liem S, Ciaffi J, Ajmone Marsan N, Ninaber M, Allaart C, Gillet van Dongen H, Goekoop R, Huizinga T, Knevel R, De Vries-Bouwstra J. New risk model is able to identify patients with a low risk of progression in systemic sclerosis. RMD Open 2021;7:e001524. [PMID: 34059523 DOI: 10.1136/rmdopen-2020-001524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Hoffmann-Vold AM, Kreuter M. One-step closer to solve the mystery of predicting disease progression in systemic sclerosis associated interstitial lung disease? Thorax 2021:thoraxjnl-2021-217811. [PMID: 34446525 DOI: 10.1136/thoraxjnl-2021-217811] [Reference Citation Analysis]
36 Jung SM, Park KS, Kim KJ. Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease. Ann Rheum Dis 2021:annrheumdis-2021-220493. [PMID: 34380701 DOI: 10.1136/annrheumdis-2021-220493] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Vandecasteele E, Melsens K, Vanhaecke A, Blockmans D, Bonroy C, Carton C, Deschepper E, De Keyser F, Houssiau F, Piette Y, Vanthuyne M, Verbeke K, Westhovens R, Wuyts WA, De Langhe E, Brusselle G, Smith V. Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort study. Semin Arthritis Rheum 2021;51:969-76. [PMID: 34403812 DOI: 10.1016/j.semarthrit.2021.07.018] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Kuwana M, Gil-Vila A, Selva-O'Callaghan A. Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis 2021;13:1759720X211032457. [PMID: 34377160 DOI: 10.1177/1759720X211032457] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
39 Pulito-Cueto V, Remuzgo-Martínez S, Genre F, Atienza-Mateo B, Mora-Cuesta VM, Iturbe-Fernández D, Lera-Gómez L, Pérez-Fernández R, Prieto-Peña D, Portilla V, Blanco R, Corrales A, Gualillo O, Cifrián JM, López-Mejías R, González-Gay MA. Endothelial Progenitor Cells: Relevant Players in the Vasculopathy and Lung Fibrosis Associated with the Presence of Interstitial Lung Disease in Systemic Sclerosis Patients. Biomedicines 2021;9:847. [PMID: 34356910 DOI: 10.3390/biomedicines9070847] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
40 Kawano-Dourado L, Lee JS. Management of Connective Tissue Disease-Associated Interstitial Lung Disease. Clin Chest Med 2021;42:295-310. [PMID: 34024405 DOI: 10.1016/j.ccm.2021.03.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Liu S, Chung MP, Ley B, French S, Elicker BM, Fiorentino DF, Chung LS, Boin F, Wolters PJ. Peripheral blood leucocyte telomere length is associated with progression of interstitial lung disease in systemic sclerosis. Thorax 2021:thoraxjnl-2020-215918. [PMID: 34272332 DOI: 10.1136/thoraxjnl-2020-215918] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
42 Bournia VK, Kallianos A, Panopoulos S, Gialafos E, Velentza L, Vlachoyiannopoulos PG, Sfikakis PP, Trakada G. Cardiopulmonary exercise testing and prognosis in patients with systemic sclerosis without baseline pulmonary hypertension: a prospective cohort study. Rheumatol Int 2021. [PMID: 34189602 DOI: 10.1007/s00296-021-04937-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Mattoo H, Pillai S. Idiopathic pulmonary fibrosis and systemic sclerosis: pathogenic mechanisms and therapeutic interventions. Cell Mol Life Sci 2021;78:5527-42. [PMID: 34145462 DOI: 10.1007/s00018-021-03874-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
44 Hoffmann-Vold AM, Molberg Ø. Detection, screening, and classification of interstitial lung disease in patients with systemic sclerosis. Curr Opin Rheumatol 2020;32:497-504. [PMID: 32890027 DOI: 10.1097/BOR.0000000000000741] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
45 Foeldvari I, Torok KS. Review for best practice in clinical rheumatology juvenile systemic sclerosis - Updates and practice points. Best Pract Res Clin Rheumatol 2021;:101688. [PMID: 33896752 DOI: 10.1016/j.berh.2021.101688] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Yoshida Y, Sugimoto T, Hosokawa Y, Suma H, Kobayashi H, Ishitoku M, Kohno H, Tokunaga T, Watanabe H, Mokuda S, Nojima T, Hirata S, Sugiyama E. C-reactive protein and ground-glass opacity as predictors for intractable interstitial lung disease in patients with systemic sclerosis under cyclophosphamide treatment regardless of concomitant glucocorticoids. Mod Rheumatol 2021;:1-8. [PMID: 33775207 DOI: 10.1080/14397595.2021.1907014] [Reference Citation Analysis]
47 Castañeda NG, Rubio ER, Emperiale V, Hajkhan AM. Esclerosis sistémica. Medicine - Programa de Formación Médica Continuada Acreditado 2021;13:1769-1778. [DOI: 10.1016/j.med.2021.04.004] [Reference Citation Analysis]
48 Vonk MC, Walker UA, Volkmann ER, Kreuter M, Johnson SR, Allanore Y. Natural variability in the disease course of SSc-ILD: implications for treatment. Eur Respir Rev 2021;30:200340. [PMID: 33762426 DOI: 10.1183/16000617.0340-2020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
49 Aringer M, Riemekasten G. Relevance of immunomodulatory therapy for interstitial lung disease in systemic sclerosis. Best Pract Res Clin Rheumatol 2021;35:101672. [PMID: 33745826 DOI: 10.1016/j.berh.2021.101672] [Reference Citation Analysis]
50 Spierings J, van Rhenen A, Welsing PM, Marijnissen AC, De Langhe E, Del Papa N, Dierickx D, Gheorghe KR, Henes J, Hesselstrand R, Kerre T, Ljungman P, van de Loosdrecht AA, Marijt EW, Mayer M, Schmalzing M, Schroers R, Smith V, Voll RE, Vonk MC, Voskuyl AE, de Vries-Bouwstra JK, Walker UA, Wuttge DM, van Laar JM. A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol. BMJ Open 2021;11:e044483. [PMID: 33737437 DOI: 10.1136/bmjopen-2020-044483] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
51 Bergmann C, Distler JHW, Treutlein C, Tascilar K, Müller A, Atzinger A, Matei A, Knitza J, Györfi A, Lück A, Dees C, Soare A, Ramming A, Schönau V, Distler O, Prante O, Ritt P, Götz TI, Köhner M, Cordes M, Bäuerle T, Kuwert T, Schett G, Schmidkonz C. 68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study. The Lancet Rheumatology 2021;3:e185-94. [DOI: 10.1016/s2665-9913(20)30421-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
52 Dobrota R, Jordan S, Juhl P, Maurer B, Wildi L, Bay-jensen A, Karsdal MA, Herrick AL, Distler JHW, Allanore Y, Hoffmann-vold A, Siebuhr AS, Distler O. Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study. The Lancet Rheumatology 2021;3:e175-84. [DOI: 10.1016/s2665-9913(20)30385-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
53 Ruaro B, Confalonieri M, Matucci-Cerinic M, Salton F, Confalonieri P, Santagiuliana M, Citton GM, Baratella E, Bruni C. The Treatment of Lung Involvement in Systemic Sclerosis. Pharmaceuticals (Basel) 2021;14:154. [PMID: 33668530 DOI: 10.3390/ph14020154] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
54 Kolb M, Chalmers JD, Humbert M. The evolution of the European Respiratory Journal: weathering the publishing pandemic. Eur Respir J 2021;57:2100084. [PMID: 33509907 DOI: 10.1183/13993003.00084-2021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Löfdahl A, Tornling G, Wigén J, Larsson-Callerfelt AK, Wenglén C, Westergren-Thorsson G. Pathological Insight into 5-HT2B Receptor Activation in Fibrosing Interstitial Lung Diseases. Int J Mol Sci 2020;22:E225. [PMID: 33379351 DOI: 10.3390/ijms22010225] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
56 Ariani A, Sverzellati N, Becciolni A, Milanese G, Silva M. Using quantitative computed tomography to predict mortality in patients with interstitial lung disease related to systemic sclerosis: implications for personalized medicine. Expert Review of Precision Medicine and Drug Development 2021;6:31-40. [DOI: 10.1080/23808993.2021.1858053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Tang IYK, Ho S. Treatment of Systemic Sclerosis Associated Interstitial Lung Disease. Journal of Clinical Rheumatology and Immunology 2020;20:56-64. [DOI: 10.1142/s2661341720300050] [Reference Citation Analysis]
58 Kaniecki T, Abdi T, McMahan ZH. Clinical Assessment of Gastrointestinal Involvement in Patients with Systemic Sclerosis. Med Res Arch 2020;8:2252. [PMID: 34337149 DOI: 10.18103/mra.v8i10.2252] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Vonk MC. Is there still a role for cyclophosphamide in the treatment of systemic sclerosis? Journal of Scleroderma and Related Disorders 2021;6:117-22. [DOI: 10.1177/2397198320961673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
60 Hoffmann-Vold AM, Allanore Y, Alves M, Brunborg C, Airó P, Ananieva LP, Czirják L, Guiducci S, Hachulla E, Li M, Mihai C, Riemekasten G, Sfikakis PP, Kowal-Bielecka O, Riccardi A, Distler O; EUSTAR collaborators. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis 2021;80:219-27. [PMID: 32988845 DOI: 10.1136/annrheumdis-2020-217455] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 25.0] [Reference Citation Analysis]
61 Park MS. Recent Advances in Predicting Mortality and Progression of Systemic Sclerosis-Associated Interstitial Lung Disease. Tuberc Respir Dis (Seoul) 2020;83:326-8. [PMID: 32898968 DOI: 10.4046/trd.2020.0100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Smith V, Vanhaecke A, Guerra MG, Melsens K, Vandecasteele E, Paolino S, Cutolo M. May capillaroscopy be a candidate tool in future algorithms for SSC-ILD: Are we looking for the holy grail? A systematic review. Autoimmunity Reviews 2020;19:102619. [DOI: 10.1016/j.autrev.2020.102619] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
63 Narváez J, LLuch J, Molina-Molina M, Vicens-Zygmunt V, Luburich P, Yañez MA, Nolla JM. Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression. Semin Arthritis Rheum 2020;50:977-87. [PMID: 32911289 DOI: 10.1016/j.semarthrit.2020.08.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
64 Scallan CJ, Collins BF, Raghu G. Systemic sclerosis-associated interstitial lung disease. Curr Opin Pulm Med 2020;26:487-95. [PMID: 32740379 DOI: 10.1097/MCP.0000000000000707] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Abignano G, Del Galdo F. Biomarkers as an opportunity to stratify for outcome in systemic sclerosis. Eur J Rheumatol 2020;7:S193-202. [PMID: 32697933 DOI: 10.5152/eurjrheum.2020.19065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
66 Hinchcliff M. Lenabasum for Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol 2020;72:1237-40. [PMID: 32368869 DOI: 10.1002/art.41302] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
67 Schniering J, Maciukiewicz M, Gabrys HS, Brunner M, Blüthgen C, Meier C, Braga-lagache S, Uldry A, Heller M, Distler O, Guckenberger M, Fretheim H, Hoffmann-vold A, Nakas CT, Frauenfelder T, Tanadini-lang S, Maurer B. Resolving phenotypic and prognostic differences in interstitial lung disease related to systemic sclerosis by computed tomography-based radiomics.. [DOI: 10.1101/2020.06.09.20124800] [Reference Citation Analysis]